Acadian Asset Management’s PhaseBio Pharmaceuticals, Inc. Common Stock PHAS Stock Holding History

Acadian Asset Management’s Portfolio PHAS Stock Details PHAS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-172,958	Closed	-$4K	–	2062
2022 Q4	$4K	Hold	172,958	–	–	﹤0.01%	1752
2022 Q3	$29K	Sell	172,958 -99,812	-37%	-$102K	﹤0.01%	1565
2022 Q2	$164K	Sell	272,770 -52,490	-16%	-$50.3K	﹤0.01%	1250
2022 Q1	$428K	Sell	325,260 -135	-0%	-$219	﹤0.01%	1041
2021 Q4	$847K	Buy	325,395 +312,845	+2,493%	+$945K	﹤0.01%	868
2021 Q3	$39K	Buy	+12,550	New	+$41.9K	﹤0.01%	1584
2020 Q2	–	Sell	-138	Closed	–	–	2385
2020 Q1	$0	Sell	138 -13,661	-99%	-$62.5K	﹤0.01%	1990
2019 Q4	$84K	Buy	13,799 +8,860	+179%	+$36.5K	﹤0.01%	1517
2019 Q3	$21K	Buy	+4,939	New	+$39.4K	﹤0.01%	1716

Acadian Asset Management's PHAS Position: Q1 2023 in Review

Acadian Asset Management sold out of PhaseBio Pharmaceuticals, Inc. Common Stock (PHAS) in Q1 2023, closing a stake of 172,958 shares — an estimated $4K sold.

Acadian Asset Management first reported a position in PHAS in Q3 2019 and held it in 9 quarters. The position peaked at $847K in Q4 2021. 0 funds tracked by Wall St. Rank hold PHAS as of Q1 2023.

Acadian Asset Management reported no remaining PhaseBio Pharmaceuticals, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
Acadian Asset Management sold 172,958 PhaseBio Pharmaceuticals, Inc. Common Stock shares in Q1 2023, an estimated $4K.
Acadian Asset Management first reported a position in PhaseBio Pharmaceuticals, Inc. Common Stock in Q3 2019 and held it in 9 quarters.
Acadian Asset Management's PhaseBio Pharmaceuticals, Inc. Common Stock position peaked at $847K in Q4 2021.
0 funds tracked by Wall St. Rank held PhaseBio Pharmaceuticals, Inc. Common Stock as of Q1 2023.

Based on Acadian Asset Management's 13F filing for Q1 2023, filed 11 May 2023.